×
Back to Agenda
Updates on China Regulatory Reform
Session Chair(s)
Ling Su, PhD
Research Fellow
Shenyang Pharmaceutical University, Yeehong Business School, China
In this forum, experts from government, academia and industry will present and discuss updates in NMAP's regulatory reform and progress in drug review and approval, and development of Chinese pharmacopeia 2020.
Learning Objective : Discuss and understand the latest progress in NMPA’s regulatory reform and the impacts on Chinese pharmaceutical regulation and drug development; Recognize China’s evolving regulatory environment and future development.
Speaker(s)
Regulatory Reform Enhancing Drug Review and Approval
Xiaoyuan Chen, PhD
Beijing Tsinghua Changgung Hospital, China
Director, GCP Officer
Regulatory Reform: Industry EWxoerience and Perspective
Xiaojun (Wendy) Yan, MD, MBA
BeiGene (Beijing) Co., Ltd., China
Senior Vice President, Senior Advisor
Brief Introduction on Chinese Pharmacopoeia 2020
Xiaoxu Hong
Chinese Pharmacopoeia Commission, China
Deputy Division Director
Have an account?